Categories: DevelopmentDrugHuman
Developing first-in-class medications for human diseases
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.11.2022 | - | $9.2M | - |
Mentions in press and media 3
| Date | Title | Description |
| 02.06.2026 | CV6 Therapeutics Appoints Dr. Chris Takimoto to Board as CV6-168 Advances Through Phase 1a | CV6 Therapeutics
Chris Takimoto, MD, PhD.
What attracted me to CV6 is the translational rationale underlying the program and its focus on enhancing the activity of therapies that remain central to cancer treatment.”
— Chris Takimoto, MD, Ph... |
| 03.11.2022 | CV6 Therapeutics Raises $9.2M in Funding | CV6 Therapeutics, a Belfast, UK-based drug development biotechnology company, raised $9.2M in funding.
Backers included QUBIS, Invest Northern Ireland, CoFund NI, and Techstart Ventures.
The company intends to use the funds to progress its ... |
| - | CV6 Therapeutics | “Early stage drug development company” |
Reviews 0
